In vivo KPT-350 treatment decreases cortical hyperexcitability following traumatic brain injury

Targeting XPO1 for fighting relapsed/refractory diseases: The research progress of XPO1 inhibitors

XPO1 is an influential member of the nuclear transporter protein family. The proteins and RNA transported by XPO1 are related to the occurrence and development of many diseases, including refractory tumor diseases and various viral infectious diseases. XPO1 is upregulated in many malignant tumors and is associated with poor prognosis. This article reviews the anti-tumor and anti-viral mechanisms of XPO1, and summarizes the biomarkers that predict the response to XPO1 inhibitors and the research progress of XPO1 as a biomarker in different diseases. In addition, we also summarize the research status of XPO1 inhibitors, and discuss the structure-activity relationship of preclinical inhibitors targeting XPO1 and the research status of XPO1 inhibitor resistance mechanisms.

Novel Approaches to Prevent Epileptogenesis After Traumatic Brain Injury

Traumatic brain injury (TBI) is defined as an alteration in brain function or other evidence of brain pathology caused by an external force. When epilepsy develops following TBI, it is known as post-traumatic epilepsy (PTE). PTE occurs in a subset of patients suffering from different types and severities of TBI, occurs more commonly following severe injury, and greatly impacts the quality of life for patients recovering from TBI. Similar to other types of epilepsy, PTE is often refractory to drug treatment with standard anti-seizure drugs. No therapeutic approaches have proven successful in the clinic to prevent the development of PTE. Therefore, novel treatment strategies are needed to stop the development of PTE and improve the quality of life for patients after TBI. Interestingly, TBI represents an excellent clinical opportunity for intervention to prevent epileptogenesis as typically the time of initiation of epileptogenesis (i.e., TBI) is known, the population of at-risk patients is large, and animal models for preclinical studies of mechanisms and treatment targets are available. If properly identified and treated, there is a true opportunity to prevent epileptogenesis after TBI and stop seizures from ever happening. With that goal in mind, here we review previous attempts to prevent PTE both in animal studies and in humans, we examine how biomarkers could enable better-targeted therapeutics, and we discuss how genetic variation may predispose individuals to PTE. Finally, we highlight exciting new advances in the field that suggest that there may be novel approaches to prevent PTE that should be considered for further clinical development.